HLA-DQA1 and ulcerative colitis: In addition to HLA-DQA1*05:01 carriage, treatment for ulcerative colitis (UC), use as a subsequent (second line) biologic, and earlier era of treatment initiation were all independently associated with a shorter time to LoR to infliximab.